Literature DB >> 30246730

Giant Axonal Neuropathy with Unusual Neuroimagings Caused by Compound Heterozygous Mutations in GAN Gene.

Shuang Cai1, Jie Lin1, Yi-Qi Liu1, Jia-Hong Lu1, Chong-Bo Zhao1.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30246730      PMCID: PMC6166460          DOI: 10.4103/0366-6999.241804

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
To the Editor: Giant axonal neuropathy (GAN) is a rare neurodegenerative disease caused by recessive mutations in GAN gene encoding gigaxonin. Nerve pathology of GAN shows typical giant axon with accumulating intermediate filaments. The disease is progressive with impairments in both peripheral and central nervous system. Here, we reported a case presenting gait disturbance, giant axon in nerve biopsy, and abnormalities in brain magnetic resonance imaging (MRI). A 13-year-old girl presented progressive gait disturbance for 7 years. She had a normal physical and cognitive developmental milestone before age 3. Thereafter, she showed motor retrogradation with slow running, gait imbalance, and exercise intolerance. She received Achilles tendon lengthening surgery at the age of 9. During the past 2 years, she felt numbness in distal lower limbs and difficult in doing buttons and using chopsticks. She was the first child of healthy nonconsanguineous parents with no family history of neuromuscular disorders. On examination, she had kinky hair, bilateral pes cavus, and hammer toes. Neurological examination revealed normal mini-mental state examination score of 30, vertical and horizontal end-gaze nystagmus. Symmetrical distal muscle atrophy was observed in both lower limbs. Muscle strengths were graded 4/5 distally of the upper limbs and 3/5 distally of the lower limbs. Tendon reflexes were normal in upper limbs, but absent in lower limbs. The superficial sensation was decreased in distal upper and lower limbs, while deep sensation was decreased in distal lower limbs. The patient had impaired finger-to-nose tests, positive Holmes rebound phenomena and mildly impaired alternating movements. and heel-to-knee-to-shin tests. Romberg's test was positive. Bilateral Babinski signs were found positive. Her gait was wide-based with foot drop, and she could neither walk on her toes nor heels. Nerve conduction velocity studies indicated predominantly axonal sensorimotor neuropathy. Full spinal X-ray showed scoliosis [Figure 1c]. Brain MRI revealed lesions around the fourth ventricle [Figure 1a and 1b]. Nerve biopsy showed moderate myelinated nerve fiber loss, several regenerative clusters, and scattered giant axons. Neurofilament accumulation in giant axons was detected by electron microscope [Figure 1d–1f].
Figure 1

(a and b) Brain MRI showed signal hyperintensity in cerebellar and the bottom of the fourth ventricle on FLAIR (white arrows). (c) Spinal X-ray revealed scoliosis. (d) Giant axon in nerve biopsy by toluidine blue staining ×400 (red arrow). (e) The axon diameter was 20.39 μm by electron microscope. (f) Neurofilaments were fulfilled in the giant axon. FLAIR: Fluid-attenuated inversion recovery; MRI: Magnetic resonance imaging.

(a and b) Brain MRI showed signal hyperintensity in cerebellar and the bottom of the fourth ventricle on FLAIR (white arrows). (c) Spinal X-ray revealed scoliosis. (d) Giant axon in nerve biopsy by toluidine blue staining ×400 (red arrow). (e) The axon diameter was 20.39 μm by electron microscope. (f) Neurofilaments were fulfilled in the giant axon. FLAIR: Fluid-attenuated inversion recovery; MRI: Magnetic resonance imaging. Next-generation sequencing was performed. She had compound heterozygous mutations which were inherited from her father and mother (c.1174G>A [p.E392K] and c.1634G>A [p.R545H] mutations in GAN gene), respectively. Mutation of c.1174G>A was predicted to be pathogenic by SIFT, PolyPhen-2, and mutation taste. Meanwhile, the mutation was highly conserved among different species. The mutation of c.1634G>A was reported in GAN patient associated with distal limb weakness and generalized areflexia.[1] Giant axonal neuropathy caused by GAN gene mutation is a rare neurodegenerative disease. GAN gene encodes gigaxonin protein which plays an important role in cytoskeleton formation by stabilizing microtubule network.[2] Till now, there are more than 80 cases of GAN mutant patients reported in literature.[3] The initial symptoms of GAN include kinky hair, progressively walking disturbance or cerebella, and cognitive impairments.[3] White matter changes on brain MRI have been reported, in many cases, diffuse or scattered, supratentorial or infratentorial. However, normal brain MRI is also commonly seen.[45] Other changes include cerebral and/or cerebellar and/or brainstem atrophy.[3] The brain MRI of reported patient with homozygous c.1634G>A mutations showed Arnold-Chiari I malformation rather than white matter changes.[1] The presence of giant axon with accumulation of neurofilaments and axonal spheroids is the hallmarks in nerve biopsy.[3] Our patient presented typical progressive sensorimotor neuropathy and cerebellar ataxia. Brain MRI showed abnormal signals along the bottom of the fourth ventricle which was typically seen in neuromyelitis optica (NMO) and in the cerebellum. However, this type of lesion was not commonly reported in GAN before and made it necessary to differentiate GAN from NMO or Wernicke disease on brain MRI. Giant axonal neuropathy caused by mutations in GAN gene should be taken into consideration for patients with early-onset, progressive sensorimotor axonal neuropathy, and central nervous system abnormality. Giant axons found in nerve biopsy, and gene test can help in making the diagnosis.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forsms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

This work is supported by the National Natural Science Foundation of China (No. 81401035), and Shanghai Health and Family Planning Commission key projects (No. 15DZ1208002).

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.

Authors:  Pascale Bomont; Michel Koenig
Journal:  Hum Mol Genet       Date:  2003-04-15       Impact factor: 6.150

2.  Phenotypic variability in giant axonal neuropathy.

Authors:  Meriem Tazir; Sonia Nouioua; Laurent Magy; Kathrin Huehne; Salima Assami; Andoni Urtizberea; Djamel Grid; Tarik Hamadouche; Bernd Rautenstrauss; Jean-Michel Vallat
Journal:  Neuromuscul Disord       Date:  2009-02-23       Impact factor: 4.296

3.  Clinical, pathological and molecular findings in two siblings with giant axonal neuropathy (GAN): report from India.

Authors:  A Nalini; N Gayathri; T C Yasha; S Ravishankar; A Urtizberea; Kathrin Huehne; Bernd Rautenstrauss
Journal:  Eur J Med Genet       Date:  2008-06-17       Impact factor: 2.708

4.  Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN).

Authors:  Olga Koop; Anja Schirmacher; Eva Nelis; Vincent Timmerman; Peter De Jonghe; Bernd Ringelstein; Vedrana Milic Rasic; Philippe Evrard; Jutta Gärtner; Kristl G Claeys; Silke Appenzeller; Bernd Rautenstrauss; Kathrin Hühne; Maria A Ramos-Arroyo; Helmut Wörle; Jukka S Moilanen; Simon Hammans; Gregor Kuhlenbäumer
Journal:  Neuromuscul Disord       Date:  2007-06-22       Impact factor: 4.296

Review 5.  Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis.

Authors:  Bethany L Johnson-Kerner; Lisa Roth; J Palmer Greene; Hynek Wichterle; Douglas M Sproule
Journal:  Muscle Nerve       Date:  2014-10       Impact factor: 3.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.